Owkin and Sanofi are expanding their partnership to develop ai agents, with the collaboration involving a multi-year effort. The partnership aims to build ai agents for drug development and discovery, although the exact scope and details of the collaboration are not entirely clear. There is also a report of a separate collaboration between Sanofi and another company, CytoReason, to advance ai-driven drug discovery, which may be related or unrelated to the Owkin partnership.